Pharmacology of Drugs for Myasthenia Gravis

Introduction

Myasthenia gravis (MG) is an autoimmune disorder characterized by fluctuating skeletal muscle weakness resulting from impaired neuromuscular transmission. The pathophysiology typically involves autoantibodies directed against components of the postsynaptic membrane, most commonly the nicotinic acetylcholine receptor (AChR). The clinical impact of MG ranges from ocular manifestations to generalized muscle weakness, potentially leading to respiratory failure. Consequently, precise pharmacologic management is essential for symptom control, reduction of exacerbations, and improvement of quality of life.

The therapeutic arsenal for MG has expanded considerably over recent decades. Initial treatment strategies focused on symptomatic cholinesterase inhibition, while newer approaches target the underlying immune dysregulation. A comprehensive understanding of these agents is therefore critical for clinicians and pharmacists, particularly when tailoring therapy to individual patient profiles.

Learning objectives

• Describe the primary drug classes employed in MG management and their pharmacologic classifications.
• Explain the mechanisms of action of cholinesterase inhibitors and immunosuppressive agents in MG.
• Summarize key pharmacokinetic properties influencing dosing regimens.
• Identify therapeutic indications, common adverse effects, and notable drug interactions.
• Recognize special considerations in subpopulations such as pregnant patients, children, and those with organ dysfunction.

Classification

Cholinesterase Inhibitors

These agents are reversible inhibitors of acetylcholinesterase (AChE) and are primarily used for symptomatic control. The most widely employed drugs include pyridostigmine and edrophonium. Although edrophonium is largely confined to diagnostic use due to its short half‑life, pyridostigmine remains the cornerstone of symptomatic therapy.

Immunosuppressive Agents

Immunosuppressants are subdivided into conventional cytotoxic drugs, antimetabolites, calcineurin inhibitors, and biologic monoclonal antibodies. Representative agents are azathioprine, mycophenolate mofetil, cyclosporine, tacrolimus, rituximab, eculizumab, and efgartigimod.

Adjunctive Therapies

These include corticosteroids, thymectomy, plasma exchange, and intravenous immunoglobulin (IVIG). While not classified as pharmacologic agents per se, they are integral to comprehensive MG management.

Novel Targeted Therapies

Emerging treatments exploit complement inhibition or Fc receptor blockade to reduce pathogenic antibody effects. Eculizumab, a complement C5 inhibitor, and efgartigimod, an FcRn antagonist, illustrate this therapeutic evolution.

Mechanism of Action

Cholinesterase Inhibitors

Acetylcholinesterase is the enzyme responsible for hydrolyzing acetylcholine (ACh) at the neuromuscular junction (NMJ). Inhibition of AChE prolongs the half‑life of ACh in the synaptic cleft, thereby enhancing the probability of ACh binding to nicotinic AChR on the postsynaptic membrane. This increased activation counteracts the deficit caused by antibody‑mediated receptor loss. Pyridostigmine binds to the catalytic serine residue of AChE, forming a reversible phosphylated complex. The hydrolysis rate is slowed, resulting in a sustained elevation of synaptic ACh concentration.

Azathioprine

Azathioprine is a pro‑drug that undergoes conversion to 6‑mercaptopurine (6‑MP) via the enzyme thiopurine methyltransferase (TPMT) and hypoxanthine–guanine phosphoribosyltransferase (HGPRT). 6‑MP is further metabolized to 6‑thioinosine monophosphate, which inhibits purine synthesis in proliferating lymphocytes. The resultant reduction in B‑cell and T‑cell populations diminishes autoantibody production. Importantly, the immunosuppressive effect is largely mediated through the inhibition of DNA synthesis in activated lymphocytes rather than direct antigen binding.

Mycophenolate Mofetil

Mycophenolate mofetil is a pro‑drug of mycophenolic acid (MPA). MPA selectively inhibits inosine monophosphate dehydrogenase (IMPDH), an enzyme pivotal for de novo guanosine nucleotide synthesis. Lymphocytes, which rely heavily on this pathway, undergo impaired proliferation. Consequently, antibody synthesis is attenuated. Unlike azathioprine, mycophenolate does not produce 6‑MP metabolites, thereby offering a distinct safety profile.

Calcineurin Inhibitors (Cyclosporine, Tacrolimus)

Calcineurin inhibitors block the phosphatase activity of calcineurin, thereby preventing dephosphorylation of the nuclear factor of activated T‑cells (NFAT). NFAT translocation into the nucleus is essential for interleukin‑2 (IL‑2) transcription, a key cytokine for T‑cell proliferation. By inhibiting IL‑2 synthesis, these agents suppress T‑cell activity and, indirectly, B‑cell help. Cyclosporine forms a complex with cyclophilin, whereas tacrolimus binds FK506‑binding protein (FKBP), each subsequently inhibiting calcineurin.

Rituximab

Rituximab is a chimeric monoclonal antibody that targets CD20, a surface antigen expressed on pre‑B and mature B cells. Binding of rituximab leads to B‑cell depletion via complement‑mediated cytotoxicity, antibody‑dependent cellular cytotoxicity, and apoptosis. The reduction in circulating B cells translates to decreased autoantibody synthesis, thereby ameliorating MG symptoms.

Eculizumab

Eculizumab is a humanized monoclonal antibody that binds to complement protein C5, preventing its cleavage into C5a and C5b. The downstream formation of the membrane attack complex (MAC) is thus inhibited, reducing complement‑mediated damage to the postsynaptic membrane. As complement activation is a pathway implicated in MG pathogenesis, eculizumab offers a targeted therapeutic approach.

Efgartigimod

Efgartigimod is a truncated fragment of the neonatal Fc receptor (FcRn) that binds to the IgG Fc region with high affinity. By competitively inhibiting FcRn‑mediated recycling of IgG, it accelerates the catabolism of pathogenic IgG antibodies, including anti‑AChR antibodies. This leads to a rapid reduction in circulating autoantibody titers.

Pharmacokinetics

Cholinesterase Inhibitors

Pyridostigmine

Absorption occurs primarily in the small intestine, with a bioavailability of about 50 %. Peak plasma concentrations (C_max) are reached within 1–2 h post‑oral administration. Distribution is characterized by extensive tissue binding, with a volume of distribution (V_d) of approximately 1.0 L kg^-1. The drug is metabolized by hepatic enzymes, predominantly via 6‑hydroxylation, and excreted in urine and bile. The elimination half‑life (t_1/2) ranges from 2.5 to 3.5 h. Dosing is typically 30–60 mg orally, divided into 2–4 daily administrations, with adjustments based on clinical response and side‑effect profile.

Edrophonium

Edrophonium is rapidly absorbed, with a t_max of 5 min. The drug is almost entirely hydrolyzed by plasma cholinesterase, yielding inactive metabolites. Consequently, the half‑life is extremely short (≈ 3–5 min). Due to its pharmacokinetic profile, edrophonium is mainly reserved for short‑term diagnostic testing rather than chronic therapy.

Azathioprine

Azathioprine is well absorbed orally, with a bioavailability of 70–80 %. Conversion to 6‑MP is influenced by TPMT activity; patients with low TPMT activity may exhibit higher plasma 6‑MP levels. The drug is extensively metabolized in the liver and excreted via renal and biliary routes. The t_1/2 of 6‑MP is approximately 12 h. A typical maintenance dose ranges from 1–3 mg kg^-1 daily, adjusted for therapeutic response and hematologic tolerance.

Mycophenolate Mofetil

Mycophenolate mofetil demonstrates rapid absorption, with peak plasma MPA concentrations occurring 0.5–1 h after dosing. The drug undergoes hydrolysis to MPA, which is subsequently glucuronidated. Metabolic pathways involve hepatic enzymes, and the drug is primarily excreted in feces. The t_1/2 of MPA is about 17 h. Standard dosing is 1 g orally twice daily, with potential titration based on clinical response and tolerability.

Calcineurin Inhibitors

Cyclosporine

Cyclosporine is absorbed in the gastrointestinal tract, exhibiting a bioavailability of 30–50 % when administered orally. The drug is lipophilic, resulting in a large V_d (~ 100 L). Metabolism occurs predominantly via CYP3A4 in the liver and intestinal mucosa. The half‑life is variable, ranging from 8 to 10 h. Therapeutic drug monitoring is essential due to narrow therapeutic index. Typical initial dosing is 3–5 mg kg^-1 per day, split into two doses.

Tacrolimus

Tacrolimus absorption is variable, with a bioavailability of 15–20 %. The drug is extensively metabolized by CYP3A4, and enterohepatic recirculation contributes to its pharmacokinetic profile. The t_1/2 is approximately 12 h. Dosing is individualized, often starting at 0.05–0.1 mg kg^-1 daily, with adjustments guided by trough concentrations.

Rituximab

Rituximab is administered intravenously. Distribution is limited to the vascular and interstitial spaces. The drug has a biphasic elimination: an initial distribution phase with a t_1/2 of 4–6 h, followed by a terminal phase with a t_1/2 of 20–70 days. The dose of 375 mg m^-2 weekly for 4 weeks or 1 g on days 1 and 15 is common in MG. Serum concentrations decline gradually, reflecting the slow turnover of B cells.

Eculizumab

Eculizumab is given intravenously, with a half‑life of 11–20 days. The drug is cleared via the reticuloendothelial system. The standard dosing regimen includes a loading phase of 600 mg weekly for the first 4 weeks, followed by 900 mg at week 5, and then 1200 mg every 2 weeks thereafter. Maintenance dosing may be extended to every 4 weeks for patients with sustained remission.

Efgartigimod

Efgartigimod is administered intravenously, with a half‑life of approximately 5–6 days. The drug is cleared by the kidneys and the reticuloendothelial system. The recommended dosing schedule consists of 10 mg kg^-1 infused over 30 min on days 1, 3, 5, and 7 of a 4‑day cycle, repeated every 2–3 weeks as needed.

Therapeutic Uses/Clinical Applications

Cholinesterase Inhibitors

Pyridostigmine is indicated for symptomatic management across all MG phenotypes, including ocular, generalized, and crisis states. Dose escalation is guided by clinical response and the presence of cholinergic side effects. Edrophonium is primarily reserved for short‑term diagnostic testing (Tensilon test) due to its rapid onset and brief duration.

Immunosuppressive Agents

Azathioprine

Azathioprine is used as a steroid‑sparing agent in moderate to severe MG. It is effective in reducing relapse frequency and facilitating tapering of corticosteroids. The drug is also employed in patients who exhibit contraindications to other immunosuppressants.

Mycophenolate Mofetil

Mycophenolate is increasingly utilized as an alternative steroid‑sparing agent, particularly in patients with intolerance to azathioprine or in those with concomitant autoimmune disorders. Its efficacy in MG is supported by observational data and small randomized trials.

Calcineurin Inhibitors

Cyclosporine and tacrolimus are considered in refractory MG or when rapid immunosuppression is required. They are often combined with corticosteroids or other agents to achieve disease control. The use of calcineurin inhibitors is limited by nephrotoxicity and hypertension.

Rituximab

Rituximab is indicated for refractory generalized MG, especially in patients with anti‑AChR antibodies. Off‑label use is common in patients who fail or cannot tolerate conventional immunosuppressants. The drug may also be considered in MuSK‑positive MG, where B‑cell depletion yields clinical benefit.

Eculizumab

Eculizumab is approved for generalized MG patients with anti‑AChR antibodies who have inadequate response to at least one conventional immunosuppressant. Its use is particularly effective in preventing exacerbations and reducing steroid dependence.

Efgartigimod

Efgartigimod is approved for generalized MG patients with anti‑AChR antibodies who have failed at least one conventional immunosuppressant. The drug offers a rapid onset of action and a favorable safety profile in the short‑term setting.

Adjunctive Therapies

Corticosteroids

Prednisone or prednisolone is the first‑line immunosuppressive therapy in MG. The typical initial dose is 20–40 mg day^-1, gradually tapered over months. The drug reduces autoantibody production and inflammatory cytokine release.

Thymectomy

Thymectomy is recommended for patients with thymic hyperplasia or thymoma, regardless of MG severity, and improves long‑term outcomes in generalized MG. Surgical removal reduces antigenic stimulation and may lead to remission or steroid sparing.

Plasma Exchange and IVIG

Plasma exchange (plasmapheresis) is utilized in MG crisis or when rapid symptom improvement is necessary. The procedure removes circulating antibodies, providing symptomatic relief within 24–48 h. IVIG offers similar benefits by saturating Fc receptors and modulating immune responses. Both therapies are considered in severe or refractory cases.

Adverse Effects

Cholinesterase Inhibitors

Cholinergic side effects predominate, including bradycardia, gastrointestinal dysmotility (nausea, vomiting, diarrhea), bronchospasm, excessive salivation, and increased sweating. Severe adverse reactions such as cholinergic crisis (muscle paralysis, respiratory compromise) can occur if doses are excessive. The risk of constipation and urinary retention also warrants monitoring.

Azathioprine

Hematologic toxicity is a major concern, manifesting as leukopenia, thrombocytopenia, or anemia. Hepatotoxicity, manifesting as elevated transaminases, may also arise. Rarely, pancreatitis or hypersensitivity reactions (fever, rash) are reported. TPMT genotype testing is recommended before initiation to mitigate risk.

Mycophenolate Mofetil

Gastrointestinal disturbances (diarrhea, nausea, abdominal pain) are common. Hematologic effects such as anemia and leukopenia may develop, particularly in patients with pre‑existing cytopenias. Rare cases of opportunistic infections have been documented.

Calcineurin Inhibitors

Nephrotoxicity, hypertension, neurotoxicity (tremor, seizures), and hyperglycemia are notable adverse events. Long‑term use can lead to chronic kidney disease. Monitoring of serum creatinine, blood pressure, and drug levels is essential.

Rituximab

Infusion reactions (fever, chills, hypotension) are common during the first infusion. Hypogammaglobulinemia and increased infection risk, particularly reactivation of hepatitis B virus, present significant concerns. Rarely, progressive multifocal leukoencephalopathy has been reported.

Eculizumab

Inhibition of complement exacerbates susceptibility to encapsulated bacterial infections, particularly Neisseria meningitidis. Vaccination prior to therapy initiation is mandatory. Other adverse reactions include headache, hypertension, and infusion reactions.

Efgartigimod

Adverse events are generally mild, including headache, fatigue, and local infusion site reactions. Occasional reports of infections and mild thrombocytopenia have been noted. Long‑term safety data remain limited.

Adjunctive Therapies

Corticosteroids are associated with osteoporosis, hyperglycemia, hypertension, mood disorders, and increased infection risk. Plasma exchange and IVIG carry procedural risks such as hypotension, thromboembolic events, and transfusion reactions.

Drug Interactions

Cholinesterase Inhibitors

Pyridostigmine may interact with neuromuscular blocking agents, enhancing muscle weakness or prolonging paralysis. Concomitant use with anticholinergic drugs (e.g., atropine) can diminish efficacy. Antidepressants that inhibit AChE (e.g., trimipramine) may produce additive cholinergic effects.

Azathioprine

Azathioprine is metabolized by TPMT; drugs that inhibit TPMT (e.g., fluoroquinolones) can increase 6‑MP levels, heightening toxicity. Co‑administration with mercaptopurine or other purine analogues may produce synergistic myelosuppression. Hepatotoxic agents (e.g., acetaminophen) can potentiate hepatic injury.

Mycophenolate Mofetil

Mycophenolate may interact with drugs that alter renal clearance (e.g., diuretics) or affect hepatic metabolism (e.g., rifampin). Co‑administration with antacids can reduce absorption. Antifungals (e.g., ketoconazole) may increase serum concentrations.

Calcineurin Inhibitors

Cyclosporine and tacrolimus are potent inhibitors of CYP3A4 and P‑glycoprotein. Concomitant administration of macrolide antibiotics (e.g., clarithromycin) or azole antifungals (e.g., ketoconazole) can markedly elevate drug levels. Stimulants of CYP3A4 (e.g., rifampin) can reduce efficacy.

Rituximab

Rituximab may enhance the immunosuppressive effects of other agents, increasing infection risk. Concomitant use with live vaccines is contraindicated. Anti‑CD20 monoclonal antibodies may interfere with laboratory assays measuring B‑cell populations.

Eculizumab

Complement inhibitors may synergize with other immunosuppressants, raising infection risk. Concomitant use with live vaccines is contraindicated. Interactions with antibiotics are minimal, but vigilance for bacteremia remains necessary.

Efgartigimod

Because efgartigimod accelerates IgG catabolism, it may reduce the efficacy of other IgG‑based therapies (e.g., monoclonal antibodies). Potential interactions with immunoglobulin preparations used for immune support should be considered.

Adjunctive Therapies

Corticosteroids amplify the effects of immunosuppressants, increasing infection risk. Plasma exchange can remove concomitantly infused medications, necessitating dosage adjustments. IVIG may interfere with certain laboratory assays and may precipitate volume overload.

Special Considerations

Pregnancy and Lactation

Cholinesterase inhibitors are generally considered safe in pregnancy, with no significant teratogenicity reported. However, careful monitoring for fetal bradycardia is advised. Azathioprine and mycophenolate are contraindicated in pregnancy due to teratogenic potential. Calcineurin inhibitors are acceptable with close monitoring. Rituximab is classified as category D; its use is discouraged unless benefits outweigh risks. Eculizumab and efgartigimod lack sufficient data; caution is warranted. Lactation is not contraindicated with pyridostigmine, but caution with other immunosuppressants due to potential infant immunosuppression.

Pediatric Considerations

In children, dosing adjustments are guided by body weight and developmental pharmacokinetics. Pyridostigmine is the primary symptomatic agent, with careful titration to avoid cholinergic crisis. Azathioprine and mycophenolate are used cautiously, monitoring for marrow suppression. Calcineurin inhibitors require meticulous therapeutic monitoring. Plasma exchange and IVIG remain viable options in severe pediatric cases, with appropriate volume adjustments.

Geriatric Considerations

Age‑related decline in hepatic and renal function necessitates dose reduction for azathioprine, mycophenolate, and calcineurin inhibitors. Polypharmacy increases the risk of drug‑drug interactions, particularly with CYP3A4 substrates. Monitoring for falls, orthostatic hypotension, and cognitive changes is essential when using cholinesterase inhibitors.

Renal or Hepatic Impairment

Azathioprine and mycophenolate dosing should be reduced in moderate to severe renal dysfunction to avoid accumulation. Calcineurin inhibitors require dose adjustments based on renal function and serum drug levels. Hepatic impairment reduces metabolism, necessitating lower doses of all agents metabolized by the liver. Pyridostigmine clearance is primarily renal; dose reduction is advised if creatinine clearance <30 mL min^-1.

Summary / Key Points

• Symptomatic control in MG relies on cholinesterase inhibition, primarily with pyridostigmine, while rapid crisis management employs plasma exchange or IVIG.
• Immunosuppressive therapy, including azathioprine, mycophenolate mofetil, and calcineurin inhibitors, serves as steroid‑sparing agents and is essential in refractory disease.
• Biologic agents such as rituximab, eculizumab, and efgartigimod provide targeted suppression of pathogenic autoantibodies, offering options for patients unresponsive to conventional therapy.
• Therapeutic drug monitoring is indispensable for agents with narrow therapeutic indices, notably calcineurin inhibitors and rituximab.
• Safety profiles vary: cholinergic side effects dominate with pyridostigmine; hematologic toxicity is prominent with azathioprine; infection risk is heightened with biologics and complement inhibitors.
• Drug interactions must be carefully evaluated, especially concerning CYP3A4 modulation and potential additive immunosuppression.
• Special populations require individualized dosing and vigilant monitoring: pregnant patients, children, geriatrics, and those with organ dysfunction.
• Collaborative care, comprising neurologists, pharmacists, and primary clinicians, optimizes therapeutic outcomes and mitigates adverse events in MG management.

References

1. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
2. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
3. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
4. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
5. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
6. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
7. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
8. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.